It was a pleasure to speak with Professor Cynthia Aranow (Feinstein Institutes for Medical Research, Northwell Health, New York, NY, USA) around the BLISS-BELIEVE study, investigating sequential belimumab and rituximab therapy in SLE (NCT03312907).
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract entitled ‘Efficacy and Safety of Subcutaneous Belimumab (BEL) and Rituximab (RTX) Sequential Therapy in Patients with Systemic Lupus Erythematosus: The Phase 3, Randomized, Placebo-Controlled BLISS-BELIEVE Study.’ (ABSTRACT NUMBER: L13) was presented at the ACR Convergence, 5-9 November 2021.
Questions
- What are the unmet needs in the treatment of patients with systemic lupus erythematosus (SLE)? (0:25)
- What is the rationale for sequential belimumab and rituximab therapy in SLE? (1:31)
- What were the aims, design and inclusion criteria of the BLISS-BELIEVE study? (3:31)
- What were the efficacy, safety and tolerability findings of the study? (5:29)
- Following these findings, what future studies are planned? (6:43)
Disclosures: Cynthia Aranow discloses consulting for GlaxoSmithKline, Kezar Life Sciences, Bristol Myers Squibb and AstraZeneca.
Support:Â Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the virtual ACR Convergence 2021.
